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Background: Cystic fibrosis (CF) is the most common autosomal recessive disease in Caucasians; it is however, considered to be rare in the Arab
populations. Reports of the cystic fibrosis transmembrane regulator (CFTR) mutations from Arabs, especially from the Lebanese population, are
limited.
Methods: Twenty-two unrelated Lebanese families, with at least one child with CF, were studied. DNA extracts from blood samples of patients
and parents were screened for CFTR gene mutations.
Results: Eleven different mutations were identified. Of the 44 alleles studied, the most common mutations were: F508del (34%), N1303K (27%),
W1282X (7%), and S4X (7%). Five mutations – not previously reported in the Lebanese population – were identified; these are: S549N, G542X,
2043delG, 4016insG, and R117H-7T.
Conclusions: The most common CFTR mutations in addition to five mutations not previously described in the Lebanese population were
identified. Identification of CFTR mutations in the Lebanese population is important for molecular investigations and genetic counseling.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Lebanon; CFTR1. Introduction
Cystic fibrosis (CF) is an autosomal recessive genetic disorder,
most common in the Caucasian populations with an incidence
ranging from of 1 in 2500 to 1 in 3600 [1–9]. CF is caused by a
mutation in the cystic fibrosis transmembrane regulator (CFTR)
that acts as a chloride channel and a regulator of other channels
[10]. Although more than 1500 CFTR mutations have been
reported, with variable frequencies depending on ethnic and
geographic backgrounds; however, reports on CFTR mutations⁎ Corresponding author. Departments of Pediatrics and Laboratory Medicine,
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doi:10.1016/j.jcf.2010.08.001from the Arab populations are limited and the incidence of
the disease in this population is considered to be less than in
Caucasians ranging from 1 in 2560 to 1 in 15,876 [2,11,12].
The most common CFTR mutation is F508del, which accounts
for 65–85% of all reported CFTR mutations in Caucasian
populations [5,13,14]. F508del was not as frequently reported in
the Arab populations. Moreover, Arabs carry CFTR mutations
that were never described in the Caucasians [15]. In this study,
we describe the CFTR mutational spectrum in the Lebanese
population.
2. Materials and methods
A total of 22 unrelated Lebanese families with at least one
CF affected child were studied between 2004 and 2007. CFd by Elsevier B.V. All rights reserved.
Table 1
Main clinical characteristics of a sample of 22 Lebanese families with CF. (CM: consanguineous marriage, CP: clinical presentation, Pu: pulmonary, Gi:
gastrointestinal, GR: growth retardation).
Family Origin Community CM Sex CF mutations Age at diagnosis CP Sweat test
1 Bekaa Maronite No M W1282X
Mount Lebanon Maronite F 4010del4
M W1282X/4010del4 1 year Pu Positive
2 North Sunnite Yes M N1303K
North Sunnite F N1303K
M N1303K/N1303K 7 months Pu, Gi, GR Positive
3 South Shiite Yes M F508del
Shiite F F508del
M F508del/F508del 2 years Pu, Gi, GR Positive
4 Mount Lebanon Greek-orthodox Yes M F508del
Mount Lebanon Maronite F W1282X
M F508del/W1282X 2 weeks Gi Positive
5 North Sunnite No M S549N
North Sunnite F G542X
M S549N/G542X 19 years Pu, Gi Positive
6 Bekaa Sunnite Yes M N1303K
Bekaa Sunnite F N1303K
M N1303K/N1303K 8 months Gi, GR Positive
7 Beirut Maronite No M 2789+5GNA
Beirut Greek-Orthodox F F508del
M F508del/2789+5GNA 6 months Pu, Gi, GR Positive
8 North Sunnite Yes M 2043delG
North Sunnite F 2043delG
M 2043delG/2043delG 6 weeks Gi No data
9 North Sunnite Yes M R117H-7T
North Sunnite F R117H-7T
M R117H-7T/R117H-7T 3 months Pu Positive
10 South Sunnite Yes M 4016insG
South Sunnite F 4016insG
M 4016insG/4016insG 3 months Pu Positive
M 4016insG/4016insG 5 months Pu Positive
11 Mount Lebanon Maronite No M N1303K
Mount Lebanon Greek-Catholic F N1303K
M N1303K/N1303K 3 months Pu, Gi Positive
12 North Maronite No M S4X
Mount Lebanon Maronite F N1303K
M N1303K/S4X 1 month Pu, Gi, Gr Positive
13 Bekaa Greek-Catholic No M F508del
No data Maronite F 4010del4
F F508del/4010del4 11 months Pu, Gi Positive
14 No data Greek-Catholic No M W1282X
No data Maronite F F508del
F W1282X/F508del 2 years No data Positive
15 Mount Lebanon Baptist No M F508del
Mount Lebanon Maronite F N1303K
F F508del/N1303K 3 years Pu, Gi, Gr Positive
16 North Sunnite Yes M F508del
North Sunnite F F508del
F F508del/F508del 9 months Pu, Gi, Gr Negative
17 North Sunnite Yes M N1303K
Sunnite F N1303K
F N1303K./N1303K 2 years Pu, Gr Positive
18 North Sunnite No M F508del
North Sunnite F F508del
F F508del/F508del 7 months Pu, Gi, Gr Positive
19 North Maronite No M F508del
No data Maronite F F508del
M F508del/F508del 7 years Pu, Gi, Gr Positive
20 Beirut Maronite No data M S4X
No data Maronite F S4X
M S4X/S4X 9 months Pu, Gi No data
(continued on next page)
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Table 1 (continued)
Family Origin Community CM Sex CF mutations Age at diagnosis CP Sweat test
21 Beirut Sunnite Yes M N1303K
Beirut Sunnite F N1303K
F N1303K/N1303K 5 months Pu, Gr Negative
22 Beirut Sunnite Yes M F508del
Beirut Sunnite F F508del
M F508del/F508del 3 months Pu, Gi, Gr No data
408 C. Farra et al. / Journal of Cystic Fibrosis 9 (2010) 406–410diagnosis was based mainly on the clinical picture according
to the consensus criteria [16] and was confirmed when possible
by a positive sweat chloride test. The geographic origin as well
as the community, religion, sex, consanguinity, and the clinical
presentation including pulmonary, gastrointestinal, and growth
retardation were investigated (Table 1). Institutional Review
Board (IRB) approval was granted for the study and informed
consent was obtained from all participants. Blood samples were
obtained from the parents and the affected siblings. Genomic
DNA from participants was extracted from whole blood sam-
ples collected on EDTA using the salting out method. DNA
amplifications were analyzed by direct nucleotide sequencing
of exons 1, 4, 10, 11, 20, and 21 followed by sequencing of
the remaining coding and non coding regions of the gene and
as recommended by the Cystic Fibrosis Genetic Analysis Con-
sortium [4,13]. Direct nucleotide sequencing was carried out
using Big Dye terminator cycle sequencing ready reaction kit
(Applied Biosystem, New Jersey, USA). Sequence analysis
was performed on an ABI Prism 310 DNA sequencer (Applied
Biosystem, New Jersey, USA).3. Results
A total of 22 unrelated Lebanese families were screened.
Eleven of them were consanguineous (50%) and in 1 family
there was no information on consanguinity. Eleven different
mutations were identified in the 44 alleles that were studied.Table 2
Frequency of common Lebanese CFTR mutations compared to Arab CFTR mutatio
Common CFTR
mutations in the
Lebanese population
Frequency of CF alleles (%)
Lebanon a Palestine [17] Jordan [24] Syria [29
F508 del 36.3 23.5 7.4 1 patient
W1282X 13.8 10.6
N1303K 20 21
4010del4 7.5 2.3
S4X 6.3
2789+5GNA 2.5
2043delG 2.5
4016insG 2.5
R117H-7T 2.5
G542X 1.3 1.2
4096–28G→A 1.3
E672del 1.3
M952I 1.3
S549N 1.3
a Mutations in a total of 80 identified CF alleles in the Lebanese population fromThese mutations were W1282X, 4010del4, N1303K, F508del,
S549N, G542X, 2043delG, R117H-7T, 2789 + 5GNA,
4016insG, and S4X. In 14 of the 22 families (64%), the children
were homozygous for their CFTR mutations; while, in the
remaining 8 families (36%) the children were compound
heterozygous for their mutations. The most common mutations
were; F508del detected in 34% of the 44 alleles, N1303K in 27%,
W1282X in 7%, and S4X in 7% of the alleles. Five mutations
that were not previously reported in the Lebanese population
were identified, these are: S549N, G542X, 2043delG, 4016insG
and R117H-7T. The mutations with their respective clinical
characteristics are summarized in Table 1.
4. Ethnic distribution of CF mutations
The mutations 4010del4, S4X, and W1282X were only
present in Christian families, of Maronite and Greek-catholic
origins. The mutations N1303K and F508del were detected in
families from all ethnic origins in Lebanon (Table 1).
5. Discussion
Although CF is considered to be the most common auto-
somal recessive disorder in Caucasians; however, its occurrence
in Arabs is not common. Reports on CFTR gene mutations in
the Arab populations especially from the Lebanese population
are limited [2,4].ns.
] Saudi Arabia, United Arab Emirates,
Oman, Qatar, Kuwait, and Jordan [1]
Saudi Arabia
[3,25]
Bahrain [27]
12 15 7.7
1.5 3–14
7 30.8
this study combined with Desgeorges et al. (1997) [2].
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in 1997, has investigated the distribution of CFTR mutations
in Lebanon [2]. By combining the results of our study on 22
Lebanese families with those of Desgeorges et al. from 20
families, and considering these two studies as one whole
Lebanese population (total identified CF alleles=80), we can
deduce that the three most frequent mutations in Lebanese
families are F508del, N1303K, and W1282X accounting for
70.1% of CF alleles (Table 2).
Eighteen religious denominations coexist in Lebanon, with
three major groupsMuslim Sunnite,Muslim Shiite and Christian
including Maronite, Greek-catholic, and Greek-orthodox. The
mutation 4010del4 was observed only in Christian families
and was previously reported in Christian Palestinian families
[2,17]. The mutations S4X and 2789+5GNA were also only
present in Christian Maronite. These mutations were not pre-
viously reported from neighboring Arab countries. This suggests
that they may be specific to Christian religious communities.
The mutation S4X was previously reported in the Slovenian
and Brazilian populations [18–20]. The mutation 2789+5GNA
is considered a common Southern European mutation which is
also found in high frequencies in the South-Eastern Mediterra-
nean region [21–23].
Our results differ from those reported from other neigh-
boring Arab populations (Fig. 1). Table 2 compares the fre-
quency of mutations in the Lebanese population to those
from neighboring Arab populations. In populations from
Saudi Arabia, United Arab Emirates, Oman, Qatar, Kuwait,
and Jordan the most commonly reported mutations were
1548delG, I123V, F508del, 3120+1G→A, and H139L;
while F508del (7.4%–15%) and N1303K (1.5%–14%) are
not common, and the mutation W1282X is absent from these
populations (Table 2) [1,3,24–26]. In the Bahraini population,
the most common mutations are 2043delG, 548A→T,
4041C→G, and F508del accounting for 66% of CF alleles
[27]. None of the other mutations reported from the Lebanese
population are reported in the Bahraini population.Fig. 1. Most common mutations in the Middle East/Arab populations. BH:
Bahrain; IS: Israel; JR: Jordan; KW: Kuwait; LB: Lebanon; OM: Oman; PL:
Palestine; QA: Qatar; SA: Saudi Arabia; SY: Syria; and UA: United Arab
Emirates.Interestingly, the two common Arab mutations 1548delG
and H139L, which were not found in any Caucasian chromo-
somes and were suggested to originate from the native Arab
population, were absent from our study [15,28]. A possible
explanation to differences between our results and those reported
from other Arab studies may be due to the heterogeneous
backgrounds of our families in contrast to the more pure Arab
homogenous background from other studies [25].
In the Palestinian population, although F508del, N1303K,
andW1282K were commonly reported; however, the third most
common mutation in this population, 3120+1Kbdel8.6Kb, was
not observed in the Lebanese population [17]. No study was
reported from the Syrian population except for one isolated case
report about a child homozygous for F508del (Table 2) [29]. In
Israel, the most common mutations reported were also F508del,
W1282K, and N1303K, with W1282X being the most common
(31.3%–36.2%) [21,30].
Amongst Arab populations, mutation panels differ from one
country to another and in between religious denominations. In
Lebanon, multiple ethnic and demographic groups compose
the population. Our study sheds light on the CFTR genotypes in
the Lebanese population and the corresponding phenotypes.
Our finding that only 4 mutations account for 75% of CF alleles
helps simplify mutation screening in the Lebanese patients.
Taking into consideration the massive and continuous migration
flow of the Lebanese community mainly into Europe and the
Americas, proper CFTR mutational analysis in the mainland
can provide useful additional information to the descendents in
the diaspora worldwide.Conflict of interest statement
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